Last reviewed · How we verify
NCT07269639: Go-Pro-DLBCL
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 1, PHASE2 trial testing Golcadomide + Poseltinib + Rituximab in Large B-Cell Lymphoma (LBCL) in 20 participants. Not yet recruiting.
1 December 2027
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 January 2026 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 September 2028 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Golcadomide + Poseltinib + Rituximab — full drug profile →
Conditions studied
- Large B-Cell Lymphoma (LBCL) — all drugs for Large B-Cell Lymphoma (LBCL) →
Sponsor
Seoul National University Hospital
Who can join
19 and older, any sex, with Large B-Cell Lymphoma (LBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a proof-of-concept, pilot study, phase I/II clinical trial aimed at generating preliminary data on the combination of golcadomide, poseltinib, and rituximab.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07269639
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Large B-Cell Lymphoma (LBCL)
Currently open trials in the same condition.
- NCT06526793 — Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL · Phase 2 · recruiting
- NCT07461831 — CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma · Phase 2 · recruiting
- NCT07524816 — Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma · recruiting
- NCT04661020 — CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma · Phase 2 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269639 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 8 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269639.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing